1. At a Glance
Blue Jet Healthcare delivered a banger Q1 FY26 with 117.8% YoY revenue growth and 141% jump in PAT. But Mr. Market dropped the stock 10%. Why? Because even jet engines can overheat if priced at 52x earnings.
2. Introduction with Hook
If Warren Buffett and Elon Musk co-founded a pharma company, it might look like Blue Jet Healthcare. Why?
- 40%+ ROCE. ✅
- 37%+ EBITDA margin. ✅
- Zero-debt, zero-nonsense. ✅
Yet, this company got slapped -10% in a single day despite delivering a result most pharma companies would kill for. Why? Because the market finally noticed that even sugar-free saccharin isn’t free of valuation diabetes.
3. Business Model (WTF Do They Even Do?)
Blue Jet is a specialized pharma intermediate manufacturer. They’re not making Crocin or Cough Syrup — they’re in the background, making contrast media intermediates that help doctors look inside your organs without opening you up.
Core Segments:
- Contrast Media Intermediates – 68% of revenue (used in MRI/CT scan diagnostics)
- High-intensity Sweeteners – 20% (Saccharin & salts)
- Pharma Intermediates/CMO – 12% (contract manufacturing)
And no, they don’t sell to baba clinics in Chandni Chowk — their client list includes Top 3 global contrast media players.
4. Financials Overview
FY25 (vs FY24):
- Revenue: ₹1,030 Cr → ₹1,222 Cr (18.7%)
- EBITDA: ₹378 Cr → ₹454 Cr (20%)
- PAT: ₹305 Cr → ₹359 Cr (17.7%)
Q1 FY26 YOY:
